Home » Stocks » IMTX

Immatics N.V. (IMTX)

Stock Price: $10.28 USD 0.02 (0.19%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $10.40 +0.12 (1.17%) Nov 27, 4:14 PM

Stock Price Chart

Key Info

Market Cap 646.70M
Revenue (ttm) 18.45M
Net Income (ttm) -35.20M
Shares Out 62.91M
EPS (ttm) -27.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $10.28
Previous Close $10.26
Change ($) 0.02
Change (%) 0.19%
Day's Open 10.26
Day's Range 10.26 - 10.41
Day's Volume 19,701
52-Week Range 8.67 - 17.25

More Stats

Market Cap 646.70M
Enterprise Value 646.06M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 62.91M
Float n/a
EPS (basic) -27.12
EPS (diluted) -27.12
FCF / Share 4.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 10.51%
Payout Ratio n/a
Shares Short 717,931
Short Ratio 5.46
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 9.51
PS Ratio 35.05
PB Ratio 142.13
Revenue 18.45M
Operating Income -36.63M
Net Income -35.20M
Free Cash Flow 68.00M
Net Cash 638,502
Net Cash / Share 0.01
Gross Margin 100.00%
Operating Margin -198.54%
Profit Margin -190.80%
FCF Margin 368.58%
ROA n/a
ROE n/a
ROIC -38.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(75.18% upside)
Current: $10.28
Target: 18.01
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth389.36%-
Gross Profit18.453.77
Operating Income-33.01-34.41
Net Income-31.57-31.44
Shares Outstanding1.161.16
Earnings Per Share-27.13-27.02
Operating Cash Flow68.057.58
Capital Expenditures-2.14-0.41
Free Cash Flow65.917.17
Cash & Equivalents10339.37
Total Debt3.23-
Net Cash / Debt10039.37
Book Value-41.86-10.41
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immatics N.V.
Country Germany
Employees 220
CEO Harpreet Singh-Jasuja

Stock Information

Ticker Symbol IMTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMTX


Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.